Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cardiome Pharma has announced that pursuant to its agreement of July 2013, the company has begun shipping Brinavess (vernakalant intravenous) to AOP Orphan Pharmaceuticals, now making the product available to physicians and patients in Switzerland , the Czech Republic , Poland , Slovenia , Slovakia , Hungary, Latvia and Romania .
Subscribe to our email newsletter
AOP Orphan will actively call on customers in these additional markets to promote Brinavess.
Cardiome chief commercial officer Karim Lalji noted making Brinavess available in significant Central/Eastern European markets is an important milestone in the company’s agreement with AOP Orphan Pharmaceuticals.
"We are pleased that AOP Orphan has expeditiously obtained the necessary registrations to make the product available in these countries. AOP Orphan has already begun successful commercialization of BRINAVESS in Austria and we look forward to continuing success in these additional markets," Lalji added.
AOP Orphan CEO Dr Rudolf Widmann noted the company is pleased to execute on the commercialization of Brinavess in key Central/Eastern European markets.
"The synergies that exist between BRINAVESS and our cardiovascular franchise have enabled us to rapidly build on our existing customer base by offering a complementary product and developing new customer relationships which are significant to our future growth," Dr Widmann added.